Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.

You may also be interested in...



Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka

TOKYO - A string of drugs are on track for marketing approval in Japan, as the pharmaceutical subcommittee of the Pharmaceutical Affairs and Food Sanitation Council confirmed its consent for approval of 22 new drugs and additional indications

Raising The Bar For New Anticoagulants? Warfarin Genotype Study Finds Reduced Risk

Medco/Mayo study links more precise warfarin dosing through genotyping to a 30 percent reduction in hospitalization rates compared with patients not tested prior to starting therapy.

Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says

The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel